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Proteolysis of eukaryotic histone tails has emerged as an important factor in the modulation 
of cell-cycle progression and cellular differentiation. The recruitment of lysosomal cathepsin L 
to the nucleus where it mediates proteolysis of the mouse histone H3 tail has been described 
recently. Here, we report the three-dimensional crystal structures of a mature, inactive mutant 
of human cathepsin L alone and in complex with a peptide derived from histone H3. Canonical 
substrate–cathepsin L interactions are observed in the complex between the protease and the 
histone H3 peptide. Systematic analysis of the impact of posttranslational modifications at 
histone H3 on substrate selectivity suggests cathepsin L to be highly accommodating of all 
modified peptides. This is the first report of cathepsin L–histone H3 interaction and the first 
structural description of cathepsin L in complex with a substrate. 
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C
athepsin L is one of 11 human cysteine cathepsin proteases, 
which  share  a  catalytic  mechanism  and  strong  sequence 
similarity  with  the  non-specific  plant  protease,  papain1. 
All members of this cathepsin family contain lysosomal targeting 
motifs, exhibit maximal activity at acidic pH and utilize autocata-
lytic activation mechanisms. Cathepsin L predominantly exhibits 
endoprotease activity that is essential for limited endosomal and 
lysosomal proteolysis, making it an important contributor to both 
protein degradation1 and development and function of the immune 
system2,3.
Despite their predominant lysosomal localization, a role for these 
proteases, including cathepsin L, in the nucleus has been reported. 
For  example,  the  nuclear  serpin  myeloid  and  erythroid  nuclear 
termination stage-specific protein is a potent chromatin remodel-
ling protein that also efficiently inhibits cathepsins V and L4–8. Stefin 
B (cystatin B), another endogenous inhibitor of cysteine proteases, 
specifically interacts with histones H2A.Z, H2B, H3 and cathepsin L 
in the nuclei of T98G astrocytoma cells9. A serpin A3G, upon classi-
cal but not alternative activation of macrophages, exhibits increased 
localization in the nucleolus and colocalization with cathepsin L10. 
Nuclear variants of cathepsins B and V are involved in the develop-
ment of thyroid malignancies by modifying DNA-associated pro-
teins11. A role for cathepsin L in cleavage of the CUX1 transcription 
factor and the resultant acceleration of cell-cycle progression into S 
phase has also been described12–14. Furthermore, cathepsin L defi-
ciency is correlated with a global rearrangement of chromatin struc-
ture and a redistribution of posttranslationally modified histones15. 
Though the specific mechanisms underlying the nuclear localiza-
tion remain unclear, translocation has been associated with both 
truncated and proteolytically processed forms of the protease12,16.
In addition to targeting transcription factors, nuclear proteases 
have been shown to target the tail of histone H3 in yeast and mice16,17. 
In both organisms, A21 from the H3 tail appears to be the primary 
site for proteolytic processing. Though the yeast endopeptidase has 
yet to be identified, the nuclear activity from mice has been attrib-
uted to the cysteine protease, cathepsin L16.
Crystallographic  work  has  so  far  been  centred  on  inhibitor-
bound complexes of the mature, active enzyme as well as on the 
structures of inactive cathepsin mutants with intact prosegments18–
22. In this work, we have utilized a mature form of cathepsin L with 
the active site residue C25 mutated to alanine (referred to as mC25A 
hereafter) for our structural studies. We report the first structural 
characterization of a cathepsin family member in complex with a 
cognate substrate, a peptide derived from the human histone H3 tail 
(Supplementary Fig. S1). Furthermore, we have explored the effects 
of peptide length, mutations and posttranslational modifications 
(PTMs) of histone H3 on cleavage by cathepsin L.
Results
Cathepsin L active site is unperturbed by the C25A mutation. The 
structure of the apo form of the mature C25A cathepsin L mutant, 
termed  as  apo-mC25A,  was  determined  to  2.2 Å  by  molecular 
replacement using the wild-type structure of cathepsin L (derived 
from PDB 3BC3)18 as a search model (Fig. 1a). Comparison of apo-
mC25A with previously determined structures from the cathepsin 
family  yielded  excellent  alignment  with  the  mature  forms  of 
cathepsins K, L and S, for which the r.m.s. deviations range from 0.6 
to 0.8 Å over  > 200 aligned residues (Fig. 1b). Close inspection of 
the active site cleft of apo-mC25A reveals little structural difference 
compared with the wild-type active form (Fig. 1b).
Crystal structure of the mC25A-H319 − 33 complex. The papain-like 
cysteine proteases, including cathepsin L, possess substrate-bind-
ing pockets that can be divided into seven binding subsites, S4 to 
S3′, that interact with distinct amino acids of the target substrate   
and  confer  substrate  specificity  (Fig.  1c).  The  inactive  mC25A   
cathepsin L mutant was cocrystallized with a histone H3 peptide 
covering residues 19–33 of the human histone H3 tail (Fig. 1d,e). 
Electron density was only apparent for residues Q19, L20 and A21, 
which occupy the unprimed region (subsites S3, S2 and S1, respec-
tively) of the cleft (Fig. 1f). Electron-density difference map calcu-
lations revealed excellent electron densities corresponding to the 
backbone region of this peptide segment and to the side chains of 
L20 and A21 at a contour level of 3σ. Difference electron density for 
the Q19 side chain is apparent at the 2σ contour. Systematic shift-
ing of the peptide register throughout the active-site cleft placing 
other amino acids in the S2 subsite produced less satisfactory results 
during modelling and refinement (Supplementary Fig. S2). Thus, 
the apparent difference electron density coupled with the known 
preference for hydrophobic residues at the S2 subsite and other   
biochemical  data  reported  in  this  study  and  elsewhere16  led  to 
the final modelling of the QLA peptide in the active-site cleft. No   
electron density was present to support the placement of peptide 
residues along the primed region of the active-site cleft, even at low 
sigma contours.
The  P1  residue,  H3A21,  is  involved  in  a  highly  connected   
network of hydrogen bonds, which anchors its carbonyl oxygen atop 
the imidazole ring of H163, the general base in the catalytic reac-
tion. The amide nitrogen of the H3A21 residue engages in hydrogen 
bonding with the carbonyl oxygen of mC25A-D162 (Fig. 1g). The 
carbonyl oxygen of H3A21 forms a hydrogen bond with the ND1 
atom of the catalytic H163 (Fig. 1g). The conformation of H163 
from cathepsin L is further restricted through its hydrogen bond 
interactions with N187 and W189. The β-carbon of the H3A21 
residue points directly upward from the base of the active-site cleft 
and makes no specific interactions, thus permitting substitution at   
this  site  without  significant  impact  on  the  substrate  suitability   
(Fig. 1e,g).
The side chain of the P2 residue, H3L20, makes a number of 
favourable van der Waals contacts with the residues lining the S2 
subsite, including the side chain atoms of L69, M70 and A135, and 
the main chain atoms of H163 and D162 (Fig. 1g). This residue 
is additionally constrained through the formation of main chain 
hydrogen bonds with G68 of cathepsin L.
In contrast to the narrow S2 subsite, which restricts the recog-
nition of substrate residues, much more conformational plasticity 
is permissible for the S3 subsite. No specific interactions are recog-
nizable between the P3 residue H3Q19 and cathepsin L, despite   
the presence of electron density supporting its ordered placement. 
General van der Waals contacts are made with residues lining the 
lower region of the cleft: G61, E63, L69 and Y72 (Fig. 1g).
H3L20 recognition by cathepsin L is essential for activity. The 
ability of human cathepsin L to cleave peptides derived from his-
tone tails was assessed by both direct activity measurement using 
intramolecularly quenched fluorogenic (IQF) peptides (Table 1) and 
competition  assays  using  the  commercial  Z-LR-4-methyl-7-cou-
marylamide (Mca) substrate (Tables 2 and 3, Supplementary Tables 
S1 and S2). The loss of competitive inhibition for the H314 − 31L20A 
and  H314 − 31Q19A/L20A  mutant  peptides  in  our  assays  further 
underscores  the  importance  of  leucine  recognition  in  substrate 
turnover (Table 2 and Supplementary Table S1). Mutation of Q19   
to alanine in H314 − 31 (Supplementary Table S1), however, had no 
discernable effect on proteolytic processing activity, which also sup-
ports the placement of L20 in the S2 subsite of our mC25A-H319 − 33 
complex structure.
The ability of alternative histone-derived peptides to compete 
with Z-LR-Mca turnover by cathepsin L was also assessed. Peptides 
derived from a leucine-containing region of the human histone H4 
tail are also potential substrates of cathepsin L, though to a much 
lesser  extent  than  that  observed  for  longer  H3-derived  peptides 
(Supplementary Table S1).ARTICLE     
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Histone  H3  modifications  have  modest  effects  on  activity.  To 
assess the in vitro effect of PTMs, a systematic analysis of the effect 
of known histone H3 modifications on cathepsin L activity was 
undertaken. In assays using either IQF substrates or competitors 
for Z-LR-Mca, acetylation of H3K18 resulted in a modest reduction 
in activity for the H314 − 31 peptide (Tables 1 and 3, Supplementary 
Tables S1 and S2). Methylation of H3K27 or acetylation of H3Lys14 
and H3Lys23 have little impact on either Z-LR-Mca cleavage or the 
turnover of IQF substrates, though the introduction of an acetyl 
group at H3Lys18 on peptides carrying other modifications also 
results in a modest reduction of H3-substrate fitness (Supplemen-
tary Table S1). Longer H3 peptides consistently perform as the best 
competitors for the synthetic substrate (Supplementary Table S1). 
These trends hold true for assays carried out at either pH 6.0 or 7.4, 
though the absolute value of the degree of inhibition is reduced at 
pH 7.4 (Table 2).
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Figure 1 | Crystal structures of apo-mC25A and the mC25A and histone H319 − 33 peptide complex. (a) The crystal structure of the apo form of the 
mature, inactive cathepsin L mutant, mC25A. (b) Alignment of the apo-C25A structure with other cathepsin structures of PDB codes 1nPZ, 1VSn and 
3BC3 reveals no perturbation in global structure or on the conformation of residues comprising the active-site cleft on mutation of the catalytic cysteine. 
(c) The standard nomenclature designating the peptide-binding subsites of the cathepsin L active-site-binding cleft. The substrate residues apparent in 
the crystal structure are indicated in bold. (d) The crystal structure of the mC25A cathepsin L mutant in complex with a peptide derived from the human 
H3 tail corresponding to residues 19–33 of histone H3 (QLATKAARKSAPATG). Only residues Q19, L20 and A21 could be placed. (e) The Q19–A21 segment 
of the substrate peptide was fitted into unprimed subsites. The electrostatic surface of mC25A is shown with regions of negative charge indicated in red 
and positive charges in blue. (f) The Fo–Fc difference density at 3σ contour. The placement of L20 in the S2 subsite was unambiguous. (g) The H3L20 
residue occupies the S2 subsite, where it makes a variety of van der Waals contacts with the indicated mC25A side chains. As predicted from biological 
data, H3A21 occupies the S1 subsite where the S1–S1′ peptide bond would be oriented for nucleophilic cleavage.
Table 1 | Kinetic measurements for intramolecularly quenched fluorogenic (IQF) histone H3 peptide cleavage by cathepsin L.
H3 
peptides* Sequence 
kcat  
(s − 1)‡
KM 
(10 − 8 M)‡
kcat/Km 
(×106 M − 1 s − 1)‡,§
kcat/Km 
(×106 M − 1 s − 1)§,
H316–29 Abz P R K Q L A T K A A R K S A K Dnp 0.46 6.3 6.1 0.064
H316–29K18ac Abz P R Kac Q L A T K A A R K S A K Dnp 0.49 16 2.9 0.047
H316–29K23ac Abz P R K Q L A T Kac A A R K S A K Dnp 0.37 3.7 6.7 0.036
H316–29K27me2 Abz P R K Q L A T K A A R Kme2 S A K Dnp 0.51 7.3 5.3 0.036
*Peptide numbering corresponds to the sequence of the histone H3 tail. Sites of posttranslational modification are numbered.
‡Human cathepsin L.
§Obtained from fitting the complete progress curve to first-order kinetics.
Mouse cathepsin L.ARTICLE
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Discussion
To  date,  crystallographic  work  has  centred  on  inhibitor-bound 
complexes of mature, active cathepsin L, as well as on the structures 
of inactive cathepsin mutants with intact prosegments18–22. In this 
work, we have generated the mature form of the inactive cathepsin L 
C25A mutant by means of intermolecular processing of the proseg-
ment by the wild-type protease. We refer to this form of mature pro-
tease as mC25A. Subsequent inhibitor treatment and purification 
completely removed the wild-type activity from the sample and thus 
enabled, for the first time, cocrystallization with a substrate peptide. 
As previous research has identified the H3 histone tail as a novel   
in vivo target of cathepsin L in differentiating murine embryonic 
stem cells, we have determined the X-ray crystal structures of the 
apo and H319 − 33 peptide-bound forms of mC25A.
The papain-like cysteine proteases, including cathepsin L, pos-
sess substrate-binding pockets that can be divided into seven bind-
ing subsites, S4 to S3′, that interact with distinct amino acids of the 
target substrate and confer substrate specificity. Extensive investi-
gations of cathepsin L substrate specificity have identified a strong 
preference for hydrophobic residues in the S2 subsite, with some 
preference for positively charged residues in the S1 subsite. Little 
substrate discrimination is typically observed for the S3 and S4 sub-
sites. The binding of H319 − 33 by mC25A is in agreement both with 
the S2 subsite preference for hydrophobic residues (H3L20) and 
with the in vivo and in vitro cleavage data that identified the A21–
T22 peptide bond as the primary site of H3 hydrolysis by cathepsin 
L16. The orientation of H3L20 is also consistent with the predicted 
mode  of  canonical  substrate  recognition  derived  from  extensive 
studies of cathepsin L inhibitor (Fig. 2)18,19,21–25. The importance of 
leucine recognition by the S2 pocket is further highlighted by the 
loss of competitive inhibition observed for the H314 − 31L20A and 
H314 − 31Q19A/L20A mutant peptides in our assay. Leucine recog-
nition by the S2 subsite may also underlie the substrate turnover 
observed when cathepsin L is presented with leucine-containing 
peptides derived from the histone H4 tail. Furthermore, the loss of 
competitive inhibition on mutation of L20A also suggests that alter-
native peptides originating from cleavage of other peptide bonds 
between A21 and S28 of the H3 tails16 arise from the intrinsic but 
secondary exopeptidase activity of cathepsin L and not from the 
primary cleavage of alternative sites. Hence, the initiation of his-
tone H3 cleavage at the A21–T22 bond and subsequent removal of   
additional residues from the C-terminal peptide of the histone H3 
generated the six histone H3 peptide populations that begin with 
T22, K23, A24, A25, K26 and S2816. Consistently, we have deter-
mined the structure of mC25A in complex with the H319 − 33 peptide   
from several different crystals, but have not captured alternative 
residues in the S2 subsite, thus supporting A21–T22 peptide bond 
as the primary and initial site of catalysis.
Of  significant  note  from  a  structural  perspective  is  the  lack   
of  electron  density  observed  for  the  substrate  residues  in  the   
primed region. Although much speculation has pointed to a high-
affinity interaction between the substrate and cathepsin L through 
the primed region, this has neither been experimentally verified 
nor  is  necessarily  required  for  efficient  substrate  recognition  by 
cathepsin L. Of the confirmed biologically relevant substrates for 
this enzyme, few exhibit significant sequence conservation through 
the primed region, and systematic analysis of substrate preference 
by the S1′ subsite has suggested little substrate discrimination26. 
Rather, as supported by the development of cathepsin L inhibitors 
and their respective optimization for primed region compatibility, 
the primed sites, including the S1′ region, have shown remarkable 
little preference for the chemical character of the interacting part-
ner (Fig. 2b), and many inhibitor complex structures yield poor 
electron density in this region (Fig. 2)18,19,23,25. The lack of selectivity 
in primed site recognition is further underscored by the variety of 
synthetic substrates available for cathepsin L activity assays. Such 
substrates are typically composed of modified peptides whereby 
various substituents, including nitroanilides, naphthylamides and 
amido methylcoumarins, are employed for binding in the primed 
region. The negligible impact of acetylation of H3K23 on in vitro 
proteolytic activity, in our work and that of others14, is also consist-
ent with a highly accommodating prime region.
Despite the remarkable promiscuity observed for the majority of 
the substrate-binding subsites, enzyme–substrate interactions away 
from the active-site cleft also may be important in catalysis. In our 
assays, longer peptides consistently inhibit the turnover of commer-
cial Z-LR-Mca to a greater extent than shorter peptides containing 
the H3-QLAT primary cleavage site. Extension of the N-terminus 
of the substrate peptide, exemplified by the H314 − 31 and H319 − 33 pep-
tides reported here, results in the inclusion of a positively charged 
stretch of amino acids (K14APRK18). These H3 residues may interact 
with a highly negatively charged region proximal to the S3 subsite. 
The involvement of the S3 subsite and more distant interactions 
in substrate recognition is also supported by the lower activity of 
cathepsin L toward leucine-containing peptides from the histone 
H4 tail. Further structural and biochemical analyses will be essential 
Table 3 | Apparent Ki values for Z-LR-Mca cleavage by cathepsin L in the presence of the H314–31 peptides with various modifications.
H3 peptides* Sequence Ki (mM)†
H314–31 K A P R K Q L A T K A A R K S A P A 4.5
H314–31K18ac K A P R Kac Q L A T K A A R K S A P A 10.7
H314–31K23ac K A P R K Q L A T Kac A A R K S A P A 5.02
H314–31K27me2 K A P R K Q L A T K A A R Kme2 S A P A 4.55
*Peptide numbering corresponds to the sequence of the histone H3 tail. Sites of posttranslational are numbered.
†Human cathepsin L.
Table 2 | Histone H3 Leu20 recognition by cathepsin L is essential for its cleavage by cathepsin L.
H3 peptides* Sequence Inhibition (%)‡ 
pH 6.0†
Inhibition (%)‡ 
pH 7.4†
H314–31 K A P R K Q L A T K A A R K S A P A 85.4 ± 0.3 68 ± 2
H314–31L20A K A P R K Q A A T K A A R K S A P A 13 ± 1 6.7 ± 0.1
H314–31L20AK27me3 K A P R K Q A A T K A A R Kme3 S A P A 19 ± 2 1 ± 3
H314–31K27me3 K A P R K Q L A T K A A R Kme3 S A P A 84 ± 1 66 ± 2
*Peptide numbering corresponds to the sequence of the histone H3 tail. Sites of posttranslational are numbered. Mutations are shown in bold.
‡Relative to the average observed inhibition rate obtained for the unrelated peptides PPGMRme2GPPP and PPGMRme2PPMGP.
†Human cathepsin L.ARTICLE     
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for determining the relative importance of these more distant inter-
actions in substrate recognition by cathepsin L.
With regard to PTMs of the histone tails, the lack of involve-
ment of H3 PTMs in histone cleavage has been suggested previ-
ously, as the relative abundance of the peptide populations follow-
ing cathepsin L cleavage is unchanged in the presence or absence 
of PTMs along the histone H3 tail16. The possibility for modulation 
of catalytic turnover by acetylation or methylation of H3, however, 
remains. We have attempted to address this issue by systemati-
cally analysing the effect of histone H3 PTMs on the proteolysis of 
histone H3 peptides as either substrates or competitive inhibitors 
of synthetic Z-LR-Mca catalysis (Tables 1–3). At both acidic and 
neutral pH, little effect is observed in either assay employed in this 
work. Acetylation of H3K23 had no significant effect on the his-
tone H3 peptide proteolysis in our assays, which is in agreement 
with the aforementioned lack of specific interactions between the 
primed subsites of cathepsin L and the substrate peptide. Acetyla-
tion of H3K18 resulted in only a modest decrease in competitive 
activity and substrate turnover compared with the unmodified 
H3 peptide. From a structural perspective, neutralization of the   
positively charged H3K18 by acetylation weakens its interactions 
with the negatively charged S3 region. Accordingly, although the 
S3 subsite can accommodate the negative charges of Asp and Glu 
residues to some degree, they are less preferred among cathepsin L   
substrates at this site27. This is in contrast to the previous report 
of the impact of lysine acetylation on H3 cleavage by cathepsin 
L16. Duncan et al.16 report that acetylation of H3K18 results in 
a significant increase in peptide cleavage by murine cathepsin L 
at pH 7.5 when measured using an enzyme-linked immunosorb-
ent assay-based assay with an antibody specific to the primary 
H3 A21–T22 cleavage product, although this increase is not sig-
nificant at acidic pH16. Our IQF kinetic assays using the murine 
cathepsin L orthologue, however, showed a similar trend in activ-
ity to that of the human cathepsin L (Table 1). In our assays, 
murine cathepsin L is significantly less active than the human 
counterpart, but its enzymatic activity is also minimally affected 
by the introduction of an acetyl group on H3K18 and exhibits   
no significant response to acetylation at H3K23 or methylation 
on H3K27.
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Figure 2 | Structural and sequence alignment of inhibitors and substrate 
sequences in the cathepsin L cleft. (a). Superimposition of the H319 − 33 
(cyan) peptide with the cathepsin L inhibitors, AZ12878478 (yellow, 
PDB 3HHA), and S-benzyl-n-(biphenyl-4-ylacetyl)-L-cysteinyl-n′5′-
(diaminomethyl)-D-ornithyl-n-(2-phenylethyl)-L-tyrosinamide (orange, 
PDB 3BC3). In addition to the AZ12878478, an acetate ion aligning with 
the catalytic residues and a polyethylene moiety in the prime region were 
also modelled. (b) Sequence alignments of selected cathepsin L substrates 
as identified by mass spectrometry. Each protein target is subject to 
multiple site of cleavage with both canonical and atypical substrate 
recognition by the S2 pocket, though consistently there is preference for 
large and bulky hydrophobic side chains at the S2 site. 
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Figure 3 | Sequence and structural conservation among human cathepsins L and V and murine cathepsin L. (a) Structure-based sequence alignment of 
cathepsins L and V. White residues on red background indicate identical residues, red residues on white represent similar residues and the other residues 
are coloured in black. (b) Surface representation of human cathepsins L, V and murine cathepsin L. The structure of murine cathepsin L is modelled based 
on human cathepsin L. The histone H3 peptide in human cathepsin L complex structure is superimposed to human cathepsin V and murine cathepsin L 
structures for comparison.ARTICLE
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In the human genome, there are two similar proteases that had 
been called cathepsin L. The original cathepsin L was first isolated 
in the late 1970s28. In 1998, a second human protease was cloned29, 
which was first named as cathepsin L2 but is now referred to as 
cathepsin V. Human cathepsin V is very similar to cathepsin L in 
sequence (Fig. 3). The genes for human cathepsin V and cathepsin 
L are in close proximity on chromosome 9, hinting that they might 
come from recent gene duplication. In the case of the mouse, it seems 
that only one cathepsin L form exists, and it is intermediate between 
human cathepsin V and the original cathepsin L, suggesting that 
both human genes have diverged since division from the common 
ancestor of rodent and primate lineages. It has been shown before 
that human cathepsin V is much less active than human cathepsin 
L on the usual cathepsin L synthetic substrates30. Similar to human 
cathepsin V, the murine cathepsin L is also much less active than 
human cathepsin L (Table 1). Although cathepsins L and V have 
high sequence identities ( > 70%) and structural similarities (Fig. 3), 
there are still subtle structural differences along the substrate-bind-
ing cleft31, which may give rise to the proteolysis activity difference 
and substrate specificity among these cathepsin enzymes. This war-
rants further investigation in the future.
Other factors may be at play in determining the response of 
cathepsin L to PTMs of the histone H3 tail. Certainly, the possibility 
of PTM-dependent modulation of cathepsin L activity cannot be 
excluded and should also be considered within the context of nucleo-
some  and  chromatin  organization,  where  PTM  will  dictate  H3 
tail accessibility and provide an additional regulatory mechanism   
for factors associating with the histone tails. The accessibility of 
cathepsin L cleavage sites, as regulated by histone tail modifications,   
is consistent with the cell-cycle-dependent proteolysis of the histone 
tail14. Together, the regulatory mechanisms governing tail accessi-
bility and the PTM-dependent modulation of proteolytic cleavage 
may offer direction over H3 processing by cathepsin L.
Methods
Protein expression and purification. Recombinant human cathepsin L mC25A 
was produced and purified as previously described21, except that 600 nM of active 
recombinant wild-type cathepsin L (1.7% wactive/winactive) was used to process the 
enzyme at 37 °C for 48 h. Wild-type cathepsin L activity was inhibited by the 
addition of 0.26 mM L-trans-epoxysuccinylleucylamido-(4-guanidino) butane 
(E-64, Peptide Research Institute). The inactive enzyme was purified by weak 
cation exchange chromatography. Cathepsin L mC25A free of propeptide eluted at 
approximately 0.3 M NaCl from a CM Sepharose Fast Flow column using a linear 
gradient from 0 to 1 M NaCl. Mouse cathepsin L purchased as the pro form from 
R&D Systems was activated as indicated by the supplier. Activated enzyme was 
aliquoted and frozen at  − 70 °C until needed.
Peptides. All peptides were obtained through the peptide synthesis unit of  
Tufts University Core Facility. All peptides were verified by mass spectrometry. 
Fluorescent peptides were synthesized with an amino (N)-terminal fluorescein 
isothiocyanate (FITC) label, coupled by means of an Ala–His–Ala linker to the 
desired peptide sequence. IQF peptides were synthesized with N-terminal  
o-aminobenzoic acid and C-terminal lysine-2,4-dinitrophenylamide conjugates.
Crystallization and structure determination. Single chain, mature C25A 
(mC25A) was incubated with a 5 molar excess of each peptide for 30 min at 4 °C. 
Crystallization conditions were identified by means of sparse matrix screening 
using the sitting drop vapour diffusion method. The concentration of mC25A was 
7 mg ml − 1. Diffraction quality crystals were obtained by mixing equal ratios of pro-
tein and reservoir solutions. The final crystallization condition for the apo-mC25A 
crystals was 0.2 M ammonium sulphate, 0.1 M sodium acetate trihydrate, pH 4.6, 
30% polyethylene glycol 2000 monomethylether. Crystals for the mC25A-H319 − 33 
complex were obtained in 10% isopropanol, 0.1 M sodium acetate trihydrate, pH 
4.0, 22% polyethylene glycol 6000. All crystals were grown at 18 °C and required 
approximately 4 weeks to reach optimal dimensions.
All crystals were soaked in 25% glycerol, added to the final crystallization 
solution and frozen in liquid nitrogen. Synchrotron diffraction data for the 
apo-mC25A and mC25A-H319 − 33 crystals were collected at beamline 23-ID-B, 
Advanced Photon Source, Argonne National Laboratories. All data were indexed 
and scaled in HKL200032. Three-dimensional structures were determined by means 
of molecular replacement with the wild-type cathepsin L structure derived from 
the PDB 3bc3 deposition using PHASER33. Structure building and refinement were 
carried out with Coot34 and REFMAC535,36, including TLS (translation, liberation 
and screw-rotation) refinement with appropriate non-crystallographic restraints. 
The data collection and structure refinement statistics are presented in Table 4. 
Data for the mC25A-H319 − 33 complex were severely anisotropic. Data were  
collected with 95% completeness in the 2.82–2.69 Å shell and with 78.9% complete-
ness in the 2.69–2.59 Å shell. Owing to the low Rmerge and high I/sig(I) ratio, data 
binned in the 2.59–2.5 Å shell were included in the refinement. All structural 
figures were generated with PyMOL.
Enzymatic assays. Fluorescence measurements were carried out at 25 °C  
using a Perkin-Elmer LS50B fluorescence spectrophotometer equipped with  
a thermostatted cuvette holder. The fluorimeter was calibrated before use with a 
known concentration of Mca. For the substrate benzyloxycarbonyl-leucyl- 
arginine-Mca (Z-LR-Mca, Novabiochem), the excitation and emission wavelengths 
were set to 360 and 460 nm, respectively. The slits were set to 10 and 15 nm  
at the λex and λem, respectively. The concentration of Z-LR-Mca was determined  
Table 4 | Crystallographic and refinement statistics.
Data collection Apo-mC25A mC25A-H319–33
Wavelength (Å) 1.0809 0.9686
Space group P3221 P3221
unit cell parameters (Å) a=b=62.0 a=b=62.7
c=206.3 c=205.8
Resolution (Å) 25.0–2.20  
(2.28–2.20)*
40.0–2.5  
(2.59–2.5)
Reflections
  unique 24149 (2364) 15954 (983)
  Completeness (%) 99.2 (99.4) 93.5 (59.1)
  Redundancy 5.2 (4.9) 7.2 (6.9)
I/σ(I) 20.9 (2.3) 31.9 (6.0)
Rsym (I)† 8.2 (55.4) 7.4 (19.8)
Refinement
Resolution (Å) 25.0–2.2 40.0–2.5
Reflections
  number 22916 (1233) 15283 (823)
  Completeness (%) 99.2 94.6 (60.8)
  Test set (%) 5.1 5.1
Rwork 0.204 0.209
Rfree 0.244 0.270
E.S.u. (Å)‡ 0.148 0.232
Contents of A.U.§
    Protein molecules/
atoms
2/3359 2/3393
    Ligand molecules/
atoms
0 2/44
  Sugars/solvent 1/167 2/58
Mean B-factors (Å2) 23.4 34.8
  Protein 20.5 31.1
  Ligand 70
  Solvent 34.6
Ramachandran plot (%)
  Preferred 92.07 90.4
  Allowed 5.83 8
  Outlier 2.1 1.6
RMSDp from target geometry
  Bond lengths (Å) 0.005 0.003
  Bond angles (°) 0.703 0.545
PDB ID 3IV2 3K24
*Data for the highest resolution shell in parenthesis.
†Rsym(I)=ΣhklΣi|Ii (hkl) −  < I(hkl) > |/ΣhklΣi|Ii (hkl)|; for n independent reflections and I observa-
tions of a reflection; I(hkl) > -average intensity of the I observations.
‡E.S.u.—estimated overall coordinate error based on maximum likelihood.
§A.u.—asymmetric unit.
RMSD—root mean squared deviation.ARTICLE     
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by the fluorescence output upon total hydrolysis with excess protease. The  
concentration of active wild-type human and mouse cathepsin L was determined by 
titration with E-64. Before the enzymatic assay, wild-type cathepsin L was activated 
on ice for 10 min in buffer containing 100 mM Na phosphate pH 6.0 (unless speci-
fied) or pH 7.4, 100 mM NaCl, 1 mM EDTA, 0.01% Chaps and 1 mM dithiothreitol. 
The substrate was prepared in dimethylsulphoxide (DMSO). The FITC-labeled 
inhibitors were prepared in DMSO whereas the unlabelled peptides were diluted in 
100 mM Na phosphate pH 6.0 containing 100 mM NaCl. The overall concentration 
of DMSO in the cuvette was 3% v/v to ensure substrate and inhibitor solubility.
Competitive enzyme assay. The overall substrate and inhibitor concentration in 
the cuvette was 0.16 Km and 25 µM, respectively. The final enzyme concentration 
was determined to be 48 pM. The reaction was initiated upon addition of enzyme. 
Initial rates were continuously monitored assuming fast equilibrium. Rates were 
calculated for  < 5% substrate conversion for up to 0.5 min. Rates remained constant 
and linear for at least 11% substrate conversion. Percent inhibition for a given 
labelled or unlabelled peptide was determined relative to the average rate for the 
respective two peptides of unrelated sequence. However, the initial rates for the 
unrelated peptides lacking the FITC label were identical to that with buffer alone. 
All assays were performed in duplicate.
Determination of Ki through competitive inhibition. The value of the appar-
ent Ki (Kiapp) was abstracted from the –X intercept on the linear Dixon plot of 1/v 
versus [I], where Kiapp =   Ki × (1 + [S]/Km). The [S] used was 0.62 µM or 0.16 Km. The 
concentration of [E] was kept constant at 48.4 pM whereas the [peptide] was varied 
from 0–66 µM. Initial rates were monitored for  < 0.5 min, which is  < 1.4% substrate   
conversion. All kinetic runs were duplicated and the errors on the reported  
parameter are  < 18%.
Kinetic measurements with IQF substrates. Kinetic measurements on the 
IQF substrates conjugated at the N-termini with o-aminobenzoic acid and at the 
C-termini with a lysine-2,4-dinitrophenylamide were carried out as described 
above, except for the following modifications. The fluorimeter was calibrated with 
a known concentration of Abz-NH2. The increase in fluorescence due to the cleav-
age of the IQF substrates was measured at λem 420 nm upon excitation at 320 nm. 
Inner filter effect was corrected according to Lakowicz et al.37; Fcorr = Fobs × antilog 
(0.5×(ODex + ODem)), where Fcorr and Fobs is the corrected and observed fluores-
cence intensity, and ODex and ODem is the optical density of the substrate reaction 
mixture within the cuvette at the excitation and emission wavelengths. The values 
of kcat and Km were determined by fitting the steady-state rate to a quadratic single 
binding-site equation in which the change in concentration of both substrate and 
enzyme upon formation of the enzyme–substrate complex is taken into account38.  
The kinetic parameters were determined using non-linear regression analysis.  
The calculated kcat/Km values were confirmed for human cathepsin L by fitting a com-
plete progress curve generated under conditions where [S]Km to first-order kinetics 
(kobs/[E]o = kcat/Km). [S] was 0.04 Km to at least 9  Km, whereas [E] remained constant 
at 1.21 nM. Because of the high background fluorescence of the peptides, rates were 
monitored for  < 30% total substrate hydrolysis, with an average of 15% conver-
sions. All kinetic runs were duplicated and the errors on the reported parameters 
are all  < 25%. With respect to mouse cathepsin L, because of the low error on the fit, 
[S]KM can be assumed. Range of [S] used was 21–35 nM with [E] = 17.5 nM. 
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